For the Inventor, By the Inventor

Enter assignee name

Vienna, Austria

Affiris Ag

USPTO Granted Patents = 25

% Expired Patents = 56.0

CIPO Patents = 4

EPO Patents = 22

Forward Citations = 21

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Guenther Staffler (11 out of 12 patents)

Markus Mandler (10 out of 12 patents)

Frank Mattner (9 out of 22 patents)

4. Sylvia Brunner (8 out of 9 patents)

5. Claudia Juno (7 out of 8 patents)

6. Gergana Galabova (6 out of 8 patents)

7. Gabriele Winsauer (6 out of 7 patents)

8. Walter G Schmidt (6 out of 23 patents)

9. Harald Weninger (5 out of 6 patents)

10. Radmila Santic (5 out of 6 patents)

11. Achim Schneeberger (4 out of 15 patents)

12. Erika Bilcikova (4 out of 5 patents)

13. Pola Linzmayer-Hirt (4 out of 5 patents)

14. Birgit Schuh (4 out of 5 patents)

15. Edith Kopinits (4 out of 5 patents)

25 patents: Sort by Forward Citations

1. 12653872 - MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHY (2026-06-16),

2. 11065273 - Treatment and prevention of alzheimer's disease (AD) (2021-07-20),

3. 10933123 - Peptide vaccines usable for hypercholesterolemia related diseases (2021-03-02),

4. 10646565 - Treatment of alzheimer'S disease (AD) with an aluminum salt (2020-05-12),

5. 10576131 - IL-23-p19 vaccines (2020-03-03),

6. 10517935 - Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders (2019-12-31),

7. 10478454 - Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide (2019-11-19),

8. 10406197 - Substances and methods for the use in prevention and/or treatment in Huntington's disease (2019-09-10),

9. 10344062 - Method of inhibiting C5a (2019-07-09),

10. 10053518 - Substances and methods for the use in prevention and/or treatment in Huntington's disease (2018-08-21),

11. 10004791 - Peptide vaccines against PCSK9 (2018-06-26),

12. 9999659 - Treatments using a peptide and/or vaccine (2018-06-19),

13. 9964547 - Method for detecting aSyn-specific antibodies in a biological sample (2018-05-08),

14. 9724399 - Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders (2017-08-08),

15. 9669079 - PCSK9 peptide combination vaccine and method of use (2017-06-06),

AFFiRiS AG is a clinical-stage biotechnology company specialized in the development of peptide-based vaccines for the treatment of neurodegenerative diseases. With a focus on diseases like Alzheimer's, Parkinson's, and Huntington's, AFFiRiS aims to deliver disease-modifying therapy options to patients. Through its innovative proprietary technology platforms such as AFFITOME®, AFFITOME®-PCR, and AFFITOME®-MAB, the company designs and develops peptide-based vaccines targeting disease-related proteins. AFFiRiS conducts clinical trials to prove the safety and efficacy of its vaccine candidates in order to eventually bring them to market and provide better treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

25 Patents

#39 in Vienna

#143 in Austria

#25,618 in the World

Vienna, Austria

Affiris Ag

Forward Citations = 21

35 inventors:

Guenther Staffler (11 out of 12 patents)

Markus Mandler (10 out of 12 patents)

Frank Mattner (9 out of 22 patents)

4. Sylvia Brunner (8 out of 9 patents)

5. Claudia Juno (7 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…